Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies | Zendy

Shumei Kato | Zendy; Jeffrey S. Ross | Zendy; Laurie M. Gay | Zendy; Farshid Dayyani | Zendy; Jason Roszik | Zendy; Vivek Subbiah | Zendy; Razelle Kurzrock | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies

Author(s) -

Shumei Kato,

Jeffrey S. Ross,

Laurie M. Gay,

Farshid Dayyani,

Jason Roszik,

Vivek Subbiah,

Razelle Kurzrock

Publication year - 2018

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.17.00235

Subject(s) - mdm2 , gene duplication , cancer research , cancer , carcinogenesis , population , biology , gene , medicine , oncology , bioinformatics , genetics , environmental health

MDM2 amplification can promote tumorigenesis directly or indirectly through p53 inhibition. MDM2 has increasing clinical relevance because inhibitors are under evaluation in clinical trials, and MDM2 amplification is a possible genomic correlate of accelerated progression, known as hyperprogression, after anti-PD-1/PD-L1 immunotherapy. We used next-generation sequencing (NGS) to ascertain MDM2 amplification status across a large number of diverse cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research